دورية أكاديمية

miR-429 Suppresses Endometrial Cancer Progression and Drug Resistance via DDX53

التفاصيل البيبلوغرافية
العنوان: miR-429 Suppresses Endometrial Cancer Progression and Drug Resistance via DDX53
المؤلفون: Kyung-Jun Lee, Nitya Singh, Michael Bizuneh, Nam-Hyeok Kim, Hyeong Su Kim, Youngmi Kim, Jae-Jun Lee, Jung Han Kim, Jiye Kim, Soo Young Jeong, Hye-Yon Cho, Sung Taek Park
المصدر: Journal of Personalized Medicine, Vol 13, Iss 9, p 1302 (2023)
بيانات النشر: MDPI AG, 2023.
سنة النشر: 2023
المجموعة: LCC:Medicine
مصطلحات موضوعية: endometrial cancer, DDX53, miR-429, anti-cancer drug-resistance, Medicine
الوصف: (1) Background: To examine miR-429-meditated DEAD (Asp-Glu-Ala-Asp) box polypeptide 53 (DDX53) function in endometrial cancer (EC). (2) Methods: DDX53 and miR-429 levels were measured using quantitative real-time polymerase chain reaction and western blotting assays, cell invasion and migration using Transwell invasion and wound healing assays, and cell proliferation using colony-forming/proliferation assays. A murine xenograft model was also generated to examine miR-429 and DDX53 functions in vivo. (3) Results: DDX53 overexpression (OE) promoted key cancer phenotypes (proliferation, migration, and invasion) in EC, while in vivo, DDX53 OE hindered tumor growth in the murine xenograft model. Moreover, miR-429 was identified as a novel miRNA-targeting DDX53, which suppressed EC proliferation and invasion. (4) Conclusions: DDX53 and miR-429 regulatory mechanisms could provide novel molecular therapies for EC.
نوع الوثيقة: article
وصف الملف: electronic resource
اللغة: English
تدمد: 2075-4426
Relation: https://www.mdpi.com/2075-4426/13/9/1302; https://doaj.org/toc/2075-4426
DOI: 10.3390/jpm13091302
URL الوصول: https://doaj.org/article/4c73d6ac37eb4e11aca4ce651caaded5
رقم الأكسشن: edsdoj.4c73d6ac37eb4e11aca4ce651caaded5
قاعدة البيانات: Directory of Open Access Journals
الوصف
تدمد:20754426
DOI:10.3390/jpm13091302